Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29690297 | 0.88 | SLC6A4 (0.40) | PIK3CAPIK3CDPIK3CBPIK3CGATM | |
| SCHEMBL4239367 | 0.87 | KMT2A (0.49) | — | |
| SCHEMBL4236848 | 0.84 | CAPN1 (0.41) | — | |
| SCHEMBL22547624 | 0.83 | — | — | |
| SCHEMBL19867145 | 0.81 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGDPP4 | |
| SCHEMBL25733592 | 0.81 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGDPP4 | |
| SCHEMBL28176946 | 0.80 | TAAR1 (0.42) | POLBSIGMAR1TSHR | |
| SCHEMBL28175915 | 0.80 | TAAR1 (0.42) | POLBSIGMAR1TSHR | |
| SCHEMBL351195 | 0.80 | DPP4 (0.46) | PIK3CAPIK3CDPIK3CBPIK3CGDPP4 | |
| SCHEMBL20963078 | 0.80 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| CN-114380861-A | Preparation method of fosinopril sodium intermediate | 浙江华海药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | PIK3CA 2780/4885PIK3CD 3622/4885PIK3CB 3533/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | PIK3CA 2780/4885PIK3CD 3622/4885PIK3CB 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.